Sam Brusco, Associate Editor02.15.22
Boston Scientific has closed the $1.75 billion deal for interventional cardiology company Baylis Medical. Baylis offers transseptal access technologies as well as guidewires, sheaths, and dilators used in catheter-based left-heart surgeries. The deal was first announced in October.
"The close of this acquisition allows Boston Scientific to integrate the Baylis platforms with our existing electrophysiology and structural heart offerings, further strengthening our position within the highest growth cardiology markets," Boston Scientific executive VP and president of Cardiology Joe Fitzgerald told the press. "We are now the only company to pair a comprehensive access portfolio with existing left-heart therapies such as left atrial appendage closure and atrial fibrillation ablation, providing physicians with a complete toolbox to treat patients with safety, efficacy and efficiency."
Boston Scientific expects the transaction to be about one cent accretive to earnings per share in 2022. The deal is expected to be less accretive on a GAAP basis this year.
"The close of this acquisition allows Boston Scientific to integrate the Baylis platforms with our existing electrophysiology and structural heart offerings, further strengthening our position within the highest growth cardiology markets," Boston Scientific executive VP and president of Cardiology Joe Fitzgerald told the press. "We are now the only company to pair a comprehensive access portfolio with existing left-heart therapies such as left atrial appendage closure and atrial fibrillation ablation, providing physicians with a complete toolbox to treat patients with safety, efficacy and efficiency."
Boston Scientific expects the transaction to be about one cent accretive to earnings per share in 2022. The deal is expected to be less accretive on a GAAP basis this year.